Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Anemia 1

Interventions

Specimen Handling 219Magnetic Resonance Spectroscopy 196pembrolizumab 195Carboplatin 169Cisplatin 137Biopsy 130Nivolumab 127Paclitaxel 112Cyclophosphamide 109Radiotherapy 104Gemcitabine 103durvalumab 88Dexamethasone 88atezolizumab 75Rituximab 69Radiation 67Lenalidomide 67Pemetrexed 65Doxorubicin 64Bevacizumab 64Docetaxel 61Etoposide 57Ipilimumab 56olaparib 54Fluorouracil 50Prednisone 49Oxaliplatin 49venetoclax 48Taxes 48Radiosurgery 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × luspatercept × 90 days × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡